Background/Aims: Glomerular endothelial cell injury plays a crucial role in the development of diabetic nephropathy (DN). CD146, an endothelial marker, was shown to increase in chronic kidney disease (CKD), but its role in DN remains unknown. We aim to assess whether CD146 could be used to evaluate disease severity and predict renal outcomes in DN at early stages. Methods: 159 non-dialysis type 2-DN patients from 2008 to 2015 were enrolled to measure the plasma concentration of soluble CD146 (sCD146). 94 type 2 diabetes mellitus patients without DN and 100 healthy subjects were used as controls. The patients with CKD stage 1-3 were referred as early stage patients. Another independent cohort of 48 patients with biopsyproved DN was used for the immunohistochemistry study of CD146. Renal outcomes were defined as doubling of serum creatinine, initiation of renal replacement therapy or death. Results: We found that plasma level of sCD146 was upregulated and associated with renal function in DN patients. sCD146 was proved to be a more optimal marker than urine albumin creatinine ratio to evaluate disease severity in these DN patients. The kidney expression of CD146 was co-localized with endothelial marker CD31 and increased in DN. CD146 staining in kidney was correlated with the severity of pathological changes in DN patients. Survival analysis suggested that both plasma and biopsy expression of CD146 were correlated with renal outcomes. Conclusions: CD146 is associated with kidney injury and could be a good marker to predict renal outcomes in patients with early stages of DN.
Expression of Endothelial Cell Injury Marker Cd146 Correlates with Disease Severity and Predicts the Renal Outcomes in Patients with Diabetic Nephropathy
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Introduction
Diabetic nephropathy (DN) occurs in approximately 10-30% of patients with diabetes mellitus (DM) and has become the leading cause of end-stage renal disease (ESRD) in most countries [1, 2] . DN is clinically characterized by persistent albuminuria and a progressive decline of renal function. Histologically, glomerular basement membrane (GBM) thinckening, mesangial expansion and later glomerulosclerosis with classic Kimmelstein-Wilson nodules, tubulointerstitial changes and vascular lesions may be observed [3] . Albuminuria has been widely viewed as a conventional biomarker for the progression and prognosis in patients with type 2 DM (T2D). However, it has been challenged in recent years advocating that albuminuria does not uniformly predict the progression of DN and a significant proportion of patients with DM who progress to ESRD do not have overt proteinuria [4, 5] . Furthermore, renal function may be lost years before proteinuria develops, suggesting an alternative pathway of progression to severe DN [6, 7] . Therefore, it is urgent to identify better biomarkers that can more effectively evaluate the renal injuries and predict the renal outcomes at early stages of DN.
Endothelial dysfunction is well documented as an initiating event in the development of DN [8] . Impairment of endothelial glycocalyx and loss of endothelial fenestrations [9, 10] ; alteration of endothelial adhesion molecule and activation of inflammation [11, 12] are all major events in endothelial injury. However, the exact role of endothelial dysfunction in DN and how endothelial injuries contribute to the progression of DN remains largely unknown.
CD146 is a transmembrane glycoprotein that is constitutively expressed in human endothelium [13] . Studies have demonstrated the function of CD146 is not only limited to cell adhesion but also involved in cell signaling, migration, angiogenesis, proliferation and differentiation [14] [15] [16] . In addition to the membrane-anchored form of CD146, a soluble form of CD146 (sCD146) has been identified in the supernatant of cultured human endothelial cells and in the blood of healthy or diseased subjects [17] [18] [19] . The plasma concentration of sCD146 was regulated in inflammatory diseases, angiogenesis and tumor metastasis [20] [21] [22] . Recent studies have shown that sCD146 increases in chronic kidney diseases (CKD) reflecting endothelial dysfunction in these patients [18, 23] . However, the role of sCD146/ CD146 in the pathogenesis and progression of DN has not been well studied.
In the current study, we examined the circulating levels of sCD146 in plasma and renal expression of CD146 in kidney biopsies of DN patients at different CKD stages. We evaluated whether CD146 could be used to assess the severity of disease and predict renal outcomes in DN at early stages.
Materials and Methods

Patients and Cohorts
This is a retrospective cohort study comprised of two cohorts of type 2 diabetic patients who were recruited from 2008 to 2015 for the study of circulating sCD146 and kidney expression of CD146 respectively. The diagnosis of T2D and DN is based on the criteria proposed by WHO in 1999 [24] and Mogensen et al. [25] . In the study of plasma sCD146 cohort, 159 of 238 type 2 DN cases were finally eligible for the enrollment. 94 T2D patients without DN and 100 healthy subjects were enrolled as controls. While in the study of biopsy CD146 cohort, 48 of 60 adult patients with kidney biopsy were recruited with the confirmed diagnosis of DN [26] . Kidney biopsies from 8 patients with minimal change disease (MCD) and 10 nephrectomy samples were used as controls. The research protocols and exclusion criteria were presented in (Fig. 1A, B) . The study was approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People's Hospital and was carried out in full accordance with the principles of the declaration of Helsinki. Written informed consents were obtained from all participants prior to blood sampling and kidney biopsy.
Laboratory Measurements
Blood and urine samples were obtained for the laboratory measurements. The urinary albumin creatinine ratio (UACR) was determined during the period of hospitalization. The estimated glomerular [26] . 95 cases of the DN patients at CKD stages (eGFR≧60ml/min) were defined as early eGFR loss [7] .
Measurement of plasma sCD146
Blood samples were collected in tubes containing EDTA and centrifuged at 3000 rpm at 4°C for 15 min. The supernatants were aliquot and stored at −80°C until assayed. The plasma concentration of sCD146 was determined with a commercial enzyme-linked immunosorbent assay (CY-QUANT ELISA, BioCytex, Marseille, France) according to the manufacturer's instructions.
Renal Biopsy and Pathological Classification
Kidney samples were cut into 3μm sections after biopsy and stained with hematoxylin and Eosin, Periodic Acid Schiff and Masson trichrome staining. All the kidney specimens were processed for EM diagnosis. The classification of DN and histological scoring were performed by two independent renal pathologists according to the criteria of Tervaert et al. [3] .
Immunohistochemistry and immunofluorescence staining
Immunohistochemistry staining of CD146 (ABCAM, ab75769) was performed on paraffin embedded human kidney sections. A double-immunofluorescence technique was used for CD146 and endothelial marker CD31 (ABCAM, ab76533) on human frozen sections. The semi-quantitative analysis based on the positive area of CD146 was performed in both glomerulus and tubular compartment in a scale of 0-4 according to previously described [27] .
Follow-up and End-point
Follow-up was from the date of initial hospital admission to March 2016. The endpoints were defined as either one of the following: doubling of baseline serum creatine (sCr) with the level of at least 2.3mg/dl, initiation of renal replacement therapy including dialysis or renal transplantation, and death due to renal disease.
Statistical Analysis
Analysis was computed using SAS 9.4 for Windows and P<0.05 was considered significant. Data were presented as mean ± SD, median (IQR) or percentages when appropriate. T-test, Wilcoxon test and ANOVA test were employed when comparing parameters between two groups or among multiple groups. Categorical variables were compared by Chi-square tests. Receiver operating characteristic curves (ROC) for CKD stage classification by sCD146 and UACR were generated and the area under the curve (AUC) was 
Results
Patients Baseline Characteristics
Baseline clinical characteristics among healthy controls and T2D patients with or without DN were summarized in (Table 1 ). All subjects in healthy controls had negative results in the qualitative test of albuminuria. There was no statistical difference of gender, post-prandial blood glucose and low-density lipoprotein-C (LDL-C). However, DN patients were much older and had longer duration of DM course, also with higher blood pressure, higher body mass index (BMI), higher level of total cholesterol (TC) and triglyceride (TG) than healthy controls and DM patients without DN. The levels of sCr and UACR increased while levels of eGFR, hemoglobin (Hgb) and serum albumin decreased in DN patients as compared with those without DN and healthy controls.
Plasma concentration of sCD146 was upregulated in DN patients
We found increased plasma level of sCD146 in T2D when compared with healthy controls (434.7 vs 358.3 ng/ml, P<0.01), and the level of sCD146 was even higher in DN group than DM patients without DN (644.2 vs 434.7 ng/ml, P<0.01) ( Fig. 2A) . In DN patients, sCD146 levels increased at the stage 2 of CKD and peaked at the stage 3. Interestingly, a declining trend of sCD146 was observed in CKD4 and CKD5 patients probably due to the diffuse glomerular endothelial atherosclerosis in these ESRD patients (Fig. 2B ). These data suggest that sCD146 increased mostly in early stages of CKD and might be a good biomarker for early stages of DN (CKD stage 1-3). Therefore, we focused on the role of CD146 in early DN (CKD stage 1-3) for the following studies.
The association of plasma sCD146 with clinical variables in DN patients with CKD stages 1-3
Spearman analysis was conducted to study the association between plasma sCD146 and clinical variables in DN patients across all CKD stages and found sCD146 was significantly correlated with s-Alb, UACR, LDL-c, HDL-c and TC (Fig. 3A, B) in DN patients at CKD stages 1-3. After adjusting for the factors in the multivariable linear regression model, plasma sCD146 was still significantly associated with renal function in these patients (R 2 =0.580, P<0.001) ( Table 2 ). We then categorized diabetic patients with CKD stages 1-3 into 3 groups by UACR level, defined as normal (UACR<30mg/g), microalbuminuria (30≤UACR<300mg/g) and macroalbuminuria (UACR≥300 mg/g). The mean plasma levels of sCD146 was slightly increased with no statistical significance in microalbuminuria group as compared to DM patients without DN. Whereas sCD146 level was much higher in DN patients with macroalbuminuria compared to those with microalbuminuria group (684.9 vs 472.3 mg/g, P<0.001) (Fig. 4A) . In addition, a significant but weak correlation between plasma concentration of sCD146 and UACR was found in DN patients. (R 2 =0.11, P<0.01) (Fig. 4B) .
These data suggest that plasma sCD146 correlates well with renal function but poorly with albuminuria at CKD1-3.
Plasma sCD146 level is a better marker than UACR to evaluate disease severity in DN
Patients with CKD stages 1-3 ROC analysis of plasma sCD146 levels and UACR were therefore performed to determine which biomarker is better for evaluation disease severity in DN patients within CKD1-3. Data showed that in DN patients with CKD1 and CKD2, the area under the ROC curve (AUC) of sCD146 was greater than those of UACR (0.964 vs 0.818, P=0.020). The AUC of sCD146 was consistently and significantly higher in DN with CKD2 than that of UACR in CKD3 patients (0.804 vs 0.575, P=0.011) (Fig. 5A, B) . This suggests that sCD146 could be a more effective marker than UACR to evaluate disease severity in early CKD stages of DN patients. (Table  3) . Immunohistochemistry staining of CD146 was performed on paraffin embedded kidney sections of patients with DN, MCD as well as normal kidney sections of nephrectomy samples. The expression of CD146 was significantly increased in DN compared to MCD and normal kidney sections, mainly localized in glomerular tufts, kidney arterioles and tubular compartments (Fig. 6A) . Quantification of the staining revealed that more advanced stages of DN had more abundant positive areas of CD146 expression in the kidney. (Fig. 6B) . Given that CD146 is constitutively expressed in endothelial cells, we performed co-immunofluorescence staining for CD146 (green) and CD31 (red), an endothelial marker, on frozen kidney sections from DN patients and normal control. Data showed that CD146 co-localized with CD31 in glomerular endothelial cells and substantially increased in DN compared to normal controls, confirming that endothelial cell localization of CD146 and increased expression of CD146 may contribute to vascular endothelial dysfunction in DN (Fig. 6C) .
Kidney expression of CD146 is associated with disease severity in DN patients at CKD stage 1-3
To determine whether kidney expression of CD146 is associated with disease severity in DN patients at stage 1-3, we firstly examined the association of CD146 in kidney sections with clinical parameters. The intensity of CD146 expression in kidney was found to be positively correlated with sCr (R (Fig. 7A-D) , suggesting a pivotal role of this biomarker in kidney to evaluate renal function and disease severity at CKD stage 1-3. However, only a weak relationship was 
=0.18 in tubular, P<0.01).
The correlations between histopathological findings and CD146 scores were then examined in the kidneys of DN patients using the Spearman correlation coefficient. The CD146 staining score in glomeruli showed a strong correlation with glomerular class classification (r=0.49, P=0.001) and ateriosclerosis (r=0.52, P<0.001), and a weak correlation with the IFTA score (r=0.32, P=0.038), interstitial inflammation score (r=0.39, P=0.011) and arteriolar hyalinosis score (r=0.38, P=0.015). Also, CD146 score in tubular compartment was well correlated with interstitial inflammation (r= 0.53, P<0.001) and IFTA scores (r=0.42, P=0.007) ( Table 4 ). These findings suggest that the expression of CD146 in kidneys correlates with renal histopathological injury in DN patients.
CD146 was associated with the renal outcomes in DN patients at CKD stage 1-3
To evaluate the role of sCD146/CD146 in the progression and prognosis of DN, we retrospectively followed up 80 of the 95 DN patients who were at CKD stages 1-3. The medium follow-up duration was 24(IQR 12) months. During the follow-up, 19 patients (23.75%) reached the end point, including 10 patients (52.63%) had doubling of baseline sCr, 5 (26.32%) progressed to ESRD with renal replacement therapy and 4 (21.05%) were died due to renal diseases. We then categorized patients into three groups based on tertiles of sCD146 level and found that patients with higher sCD146 level tend to have a poorer renal 
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outcome comparing survival between patients with upper and lower tertiles of CD146 by Kaplan-Meier analysis (P=0.049) (Fig. 8) . Data suggests that plasma sCD146 could be a predictive marker for the progression of DN A longitudinal study was also performed in the biopsy study cohort to examine whether increased expression of CD146 in kidney was associated with renal outcomes. A total of 36 DN patients who underwent kidney biopsy were followed up for a median duration of 28 (IQR14) months and the overall renal survival rate was 80.56% in these patients. Using univariate Cox analysis, we found the expression of CD146 in kidneys of DN was strongly associated with the renal outcomes, both in glomeruli (HR=4.11 [1.66, 10.18] , P=0.002) and in tubular-interstitium (HR=7.89 [2.08, 29 .98], P=0.002), suggesting that renal expression of CD146 might be a predictive marker for the progression of DN.
Discussion
Endothelial dysfunction has been considered as a critical mechanism underlying the microvascular injury in DN [28] [29] [30] . Thus measuring biological markers of vascular endothelial function in vivo may provide insights into the progression and prognosis of DN [10, 31] . The endothelial intercellular junctions exert a key function in chronic inflammation through their ability to modulate leukocyte trafficking and play a critical role during angiogenesis. Studies have confirmed an increased expression of cell adhesion molecules, such as ICAM-1 [32, 33] , VCAM-1 [34, 35] and E-selectin [31, 36] occurs in response to the disruption of glomerular endothelial cell homeostasis in DN. CD146 has been identified as an adhesion molecule expressed at the intercellular junction of endothelial cells [15] . More recently, CD146 was found to be involved in endothelial cell activity and angiogenesis [37] [38] [39] . The membrane glycoprotein CD146 is rarely found in the blood of healthy subjects, while a soluble form of CD146, which is generated probably by extracellular shedding, proteolysis or DNA splicing from damaged endothelium, was confirmed to be increased in the peripheral circulation of patients with tumor [22] , inflammatory diseases [20] or CKD [18] , suggesting a pivotal role of this soluble biomarker in the pathogenesis of angiogenesis and vascular endothelial alteration.
In the current study, we demonstrated that T2D patients with DN showed higher plasma level of sCD146 compared with diabetic patients without DN or healthy controls. The concentration of sCD146 increased from CKD1 to CKD3 in DN patients. In addition, sCD146 was shown to correlate better with kidney injury than UACR to evaluate kidney injury in DN patients at early CKD stages. All these data suggest a critical role of sCD146 in evaluating disease severity at early stages of DN. A clinical study with a small cohort in Japan found persistently elevated circulating levels of sCD146 correlated with disease severity in DN patients [23] . However, our study demonstrated that the concentration of plasma sCD146 increased progressively in DN patients from CKD stage 1-3 and then declined slightly in [40, 41] . Nevertheless, studies have proved that glomerular endothelial cell numbers were decreased in severe DN [42] , reduced angiogenesis and capillary loss also occurred in the later stages of DN [10, 42, 43] . Based on these strong findings, it is reasonable to speculate that the down-regulation of plasma sCD146 level in severe DN patients is most likely due to the extensive glomerular sclerosis and a decline of endothelial cell number at the end stage of DN. The measurement of circulating sCD146 is a convenient and noninvasive way to assess the severity of DN. However, plasma sCD146 concentration may be changed due to various disorders including infection, trauma, tumor and some other chronic diseases [20, 22, 44, 45] . Studies showed tissue expression of CD146 was increased in active inflammatory bowel diseases [20] , rheumatoid arthritis [46] , as well as in kidney biopsies from CKD patients [18] . However, the alteration of CD146 expression in kidney tissues and its association with kidney diseases hasn't been fully understood. In this study, we were able to obtain 48 samples from early to moderate stage of DN patients, which is a reasonable sample size for the human study in the setting of DN due to the difficulty in obtaining biopsy samples of DN patients. To our knowledge, this is the first study to demonstrate a clear association of CD146 expression in kidney with clinical findings in DN. CD146 was confirmed to be colocalized with CD31 in kidney arterioles and glomeruli tufts, suggesting a pivotal role of CD146 in kidney endothelium. Interestingly, CD146 was found not only restrict to glomerular endothelial cells, but was also abundant in tubular compartment of DN patients, indicating the multifunctional role of CD146 in kidney cells. Immunochemistry assessment of kidney biopsy specimens showed increased expression of CD146 was associated with the severity of renal function in DN patients, which was consistent with the findings on circulating sCD146 levels in DN patients at early CKD stages. Since histological classification is a golden standard for both diagnosis and evaluation of DN, we performed histological scoring on each kidney section in DN patients. We found CD146 scoring in either glomeruli or tubular compartment could be a valuable marker evaluating glomerular endothelial injury, vascular angiogenesis, inflammatory infiltration, and tubular interstitial fibrosis in DN. The increased expression of CD146 in kidney was synchronized with the elevated plasma level of sCD146 in DN patients with early CKD stages, corroborating a reliable and synergetic role of both CD146 and sCD146 in evaluating disease severity and progression of DN.
Currently it is still challenged to identify early DN patients who are at high risk of developing progressive nephropathy [47] . Studies have indicated that albuminuria failed to be a specific prognostic biomarker for the progressive DN, especially when urinary albumin excretion is <300 mg /24 h [6, 48] . In patients with DN, circulating sCD146 has been shown to be elevated when compared with the non-diabetic population or T2D without DN [49, 50] . However, these studies had small sample sizes and were unable to ascertain whether sCD146 could be used as biomarkers to predict patients at risk of progressive DN. A very recent study by Ilie et al. [22] demonstrated that plasma sCD146 levels together with circulating endothelial cells (CECs) counts were associated with clinical outcome in non-small cell lung cancer (NSCLC) patients undergoing surgery, suggesting a predictive role of sCD146 in tumor metastasis and prognosis. Hereby we first conduct a survival study of sCD146/CD146 in DN patients. We report that both plasma concentration of sCD146 and the intensity of CD146 expression in kidney sections predict renal outcomes and progression at early stages of DN.
The study has several potential concerns and limitations. It's a single center and retrospective cohort study with relatively limited sample size, including two independent data sets from plasma and biopsy cohorts respectively. It would be more persuasive if we could recruit DN patients who have both blood and kidney biopsy samples, with long-term follow-up from early disease stage, to evaluate the role of sCD146/CD146 in the progression of DN. The result of survival analysis for biopsy-proven DN patients was not strong enough due to the limited sample size and small event number. Moreover, since the pathogeneses of DN is multifactorial, a single biomarker might not be strong enough to predict the disease progression for DN. Finally, the underlying mechanisms explaining how CD146 contributes to the progression of DN require further investigation.
In conclusion, our findings demonstrate that sCD146/CD146 could be a useful biomarker to evaluate disease severity and predict renal outcomes in patients with early stages of DN. The aberrant expression of CD146 may reflect underlined endothelial dysfunction and vascular angiogenesis in DN.
Cellular Physiology
and Biochemistry Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
